20/20 Biolabs Reports 36.5% Revenue Growth in Q2 2026 Despite Increased Net Loss

20/20 Biolabs, Inc. reported its financial results for the second quarter of 2026, revealing a revenue of $730,571, a 36.5% increase from $535,060 in the same period last year. The company’s gross profit also saw significant growth, rising to $304,727 from $163,264, resulting in a gross margin of 41.7%, up from 30.5%. However, the company recorded a net loss of $1,506,343 for the quarter, compared to a loss of $840,933 in the prior year, reflecting a 79.1% increase in losses.

For the first half of 2026, total revenues decreased slightly to $1,083,946 from $1,088,880 in the first half of 2025. This decline was attributed to reduced sales from the BioCheck product line and the CLIAx service, which were partially offset by a 6.5% increase in OneTest sales, driven by expanded adoption among Maryland fire departments through a state-funded cancer screening program. The cost of revenues decreased to $716,335, resulting in a gross profit of $367,611, up from $329,058 in the previous year.

The company’s operating expenses surged to $3,055,190 for the first half of 2026, compared to $1,946,910 in the same period last year, primarily due to increased sales, general, and administrative expenses associated with public company costs and the launch of new products. Research and development expenses also rose to $411,114, reflecting ongoing investments in product development. The total net loss for the first half of 2026 was $3,681,180, a significant increase from $1,605,511 in the prior year.

In terms of operational metrics, 20/20 Biolabs reported a substantial increase in cash and cash equivalents, which rose to $4,546,140 as of June 30, 2026, compared to $1,025,987 at the end of 2025. The company raised $6 million through a private placement and convertible debt to support its operations. The total number of shares outstanding increased to 12,770,303, reflecting the conversion of preferred stock into common stock and the issuance of new shares.

Looking ahead, 20/20 Biolabs remains focused on expanding its product offerings and market presence, particularly with its OneTest for Cancer and the newly launched OneTest for Longevity. The company is also addressing its internal control weaknesses and plans to enhance its financial reporting processes. Despite the challenges, management believes that the recent capital raises and strategic initiatives will position the company for future growth.